Bengaluru, India

Poornima Shetty


 

Average Co-Inventor Count = 6.5

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2021

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Poornima Shetty: Innovator in Neuropharmacology

Introduction

Poornima Shetty is a distinguished inventor based in Bengaluru, India. She has made significant contributions to neuropharmacology, holding a total of four patents. Her innovative work focuses on the development of selective NR2B antagonists, which are essential in treating various central nervous system disorders.

Latest Patents

Among her notable patents are two related to selective NR2B antagonists. The first patent discloses compounds of formula I, including their salts, and discusses the use of these compounds as ligands for the NR2B receptor. This innovation signifies a crucial advancement in the treatment of disorders affecting the central nervous system. The second patent similarly provides compounds of Formula (I) and their pharmaceutically acceptable salts, reaffirming their role as ligands for the NR2B N-Methyl-D-aspartate (NMDA) receptor, underscoring their potential therapeutic applications.

Career Highlights

Currently, Poornima is affiliated with Bristol Myers Squibb Company, where she continues to push the boundaries of pharmaceutical research and development. Her innovative spirit and dedication to science have positioned her as a respected figure in her field.

Collaborations

In her career, Poornima has had the opportunity to collaborate with esteemed colleagues such as Imadul Islam and Srinivasan Thangathirupathy. These collaborations have undoubtedly enriched her research experience and have contributed to her inventive journey.

Conclusion

Poornima Shetty's work illustrates the potential impact of innovative pharmaceutical research on global health. Her patents on selective NR2B antagonists reflect her commitment to finding solutions for complex neurological disorders, paving the way for new treatment options in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…